Literature DB >> 22959509

MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma.

Xiao Gao1, Run Zhang, Xiaoyan Qu, Min Zhao, Sensen Zhang, Hanxin Wu, Li Jianyong, Lijuan Chen.   

Abstract

Multiple myeloma (MM) is characterized by a profound genomic instability of potential prognostic relevance. Loss of chromosome 13, observed in almost half of patients, negatively affects prognosis. MiR-15a, miR16-1 and miR-17-92 cluster, located on 13q, play important roles in the regulation of cell proliferation, differentiation and apoptosis. Therefore, we investigated a possible correlation of miRNA expression with chromosome 13 deletions (del(13)) and prognosis. We measured the expression of miR-15a, miR16-1 in 70 newly diagnosed MM patients and miR-17-92 cluster in 85 newly diagnosed MM patients by quantitative real-time PCR analyses. MiR-15a, miR-16-1 and miR-17-92 cluster expression levels are independent of the del(13). High levels of miR-15a, miR-16-1, miR-17, miR-20a and miR-92-1 are associated with shorter progression-free survival (PFS), suggesting poor prognosis. Our data suggest that the expression of specific miRNAs may be contributing to MM prognosis.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959509     DOI: 10.1016/j.leukres.2012.08.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  36 in total

1.  Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma.

Authors:  Jing Peng; Asmitananda Thakur; Shuo Zhang; Yuanfeng Dong; Xiaoqin Wang; Ruili Yuan; Kaige Zhang; Xuan Guo
Journal:  Tumour Biol       Date:  2015-06-02

2.  Down-regulation of miR-20a-5p triggers cell apoptosis to facilitate mycobacterial clearance through targeting JNK2 in human macrophages.

Authors:  Guoliang Zhang; Xi Liu; Wenfei Wang; Yi Cai; Shaoyuan Li; Qi Chen; Mingfeng Liao; Mingxia Zhang; Gucheng Zeng; Boping Zhou; Carl G Feng; Xinchun Chen
Journal:  Cell Cycle       Date:  2016-08-05       Impact factor: 4.534

Review 3.  The validity of circulating microRNAs in oncology: five years of challenges and contradictions.

Authors:  J Jarry; D Schadendorf; C Greenwood; A Spatz; L C van Kempen
Journal:  Mol Oncol       Date:  2014-03-06       Impact factor: 6.603

4.  Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.

Authors:  Eckart Meese; Friedrich A Grässer; Hiresh Ayoubian; Nicole Ludwig; Tobias Fehlmann; Jennifer Menegatti; Laura Gröger; Eleni Anastasiadou; Pankaj Trivedi; Andreas Keller
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 5.  MicroRNA theragnostics for the clinical management of multiple myeloma.

Authors:  N Ahmad; S Haider; S Jagannathan; E Anaissie; J J Driscoll
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

6.  Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression.

Authors:  Lei Zhang; Lin Zhou; Meng Shi; Yong Kuang; Lei Fang
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

7.  Prognostic significance of microRNA-16 expression in human colorectal cancer.

Authors:  Jun Qian; Bin Jiang; Min Li; Juan Chen; Mingzhi Fang
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

Review 8.  Plasma cells in immunopathology: concepts and therapeutic strategies.

Authors:  Benjamin Tiburzy; Upasana Kulkarni; Anja Erika Hauser; Melanie Abram; Rudolf Armin Manz
Journal:  Semin Immunopathol       Date:  2014-04-17       Impact factor: 9.623

Review 9.  mir-17-92: a polycistronic oncomir with pleiotropic functions.

Authors:  Virginie Olive; Qijing Li; Lin He
Journal:  Immunol Rev       Date:  2013-05       Impact factor: 12.988

10.  Elevated expressions of serum miR-15a, miR-16, and miR-17-5p are associated with acute ischemic stroke.

Authors:  Jin Wu; Kang Du; Xiang Lu
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.